Syros Pharmaceuticals’ (SYRS) Buy Rating Reaffirmed at Cowen and Company
A number of other equities research analysts have also recently issued reports on the stock. Zacks Investment Research cut shares of Syros Pharmaceuticals from a buy rating to a hold rating in a report on Wednesday, July 19th. ValuEngine raised shares of Syros Pharmaceuticals from a sell rating to a hold rating in a report on Monday, July 17th. Oppenheimer Holdings, Inc. set a $28.00 target price on shares of Syros Pharmaceuticals and gave the company a buy rating in a report on Monday, June 12th. Finally, Wedbush reissued an outperform rating and set a $22.00 target price on shares of Syros Pharmaceuticals in a report on Tuesday, May 16th. Four equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. The company presently has a consensus rating of Buy and a consensus price target of $20.81.
Shares of Syros Pharmaceuticals (NASDAQ:SYRS) traded up 3.61% during trading on Wednesday, hitting $21.81. The stock had a trading volume of 50,862 shares. Syros Pharmaceuticals has a 52 week low of $8.50 and a 52 week high of $24.38. The company’s market capitalization is $572.73 million. The company’s 50 day moving average price is $19.45 and its 200 day moving average price is $15.40.
Syros Pharmaceuticals (NASDAQ:SYRS) last posted its quarterly earnings data on Wednesday, August 9th. The company reported ($0.52) EPS for the quarter, beating the consensus estimate of ($0.55) by $0.03. Analysts predict that Syros Pharmaceuticals will post ($2.09) earnings per share for the current year.
In related news, Director Richard A. Young sold 3,282 shares of the stock in a transaction on Tuesday, July 25th. The stock was sold at an average price of $22.09, for a total value of $72,499.38. Following the transaction, the director now owns 423,383 shares of the company’s stock, valued at $9,352,530.47. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Eric R. Olson sold 2,500 shares of the stock in a transaction on Monday, August 7th. The shares were sold at an average price of $23.59, for a total value of $58,975.00. Following the completion of the transaction, the insider now directly owns 2,500 shares in the company, valued at approximately $58,975. The disclosure for this sale can be found here. In the last three months, insiders sold 18,282 shares of company stock worth $404,599.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. FMR LLC boosted its position in Syros Pharmaceuticals by 11.9% in the second quarter. FMR LLC now owns 3,926,998 shares of the company’s stock worth $63,185,000 after buying an additional 418,061 shares in the last quarter. Vanguard Group Inc. raised its stake in Syros Pharmaceuticals by 189.6% in the second quarter. Vanguard Group Inc. now owns 382,603 shares of the company’s stock valued at $6,156,000 after buying an additional 250,507 shares during the last quarter. Northern Trust Corp raised its stake in Syros Pharmaceuticals by 75.4% in the second quarter. Northern Trust Corp now owns 58,070 shares of the company’s stock valued at $935,000 after buying an additional 24,972 shares during the last quarter. New York State Common Retirement Fund raised its stake in Syros Pharmaceuticals by 167.9% in the second quarter. New York State Common Retirement Fund now owns 13,400 shares of the company’s stock valued at $216,000 after buying an additional 8,399 shares during the last quarter. Finally, Nationwide Fund Advisors raised its stake in Syros Pharmaceuticals by 249.8% in the second quarter. Nationwide Fund Advisors now owns 7,024 shares of the company’s stock valued at $113,000 after buying an additional 5,016 shares during the last quarter. 49.45% of the stock is currently owned by institutional investors and hedge funds.
About Syros Pharmaceuticals
Syros Pharmaceuticals, Inc is a biopharmaceutical company. The Company offers a gene control platform designed to analyze the unexploited region of deoxyribonucleic acid (DNA) in human disease tissue to identify and drug targets linked to genomically defined patient populations. The Company is focused on developing treatments for cancer and immune-mediated diseases and is building a pipeline of gene control medicines.
Receive News & Ratings for Syros Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.